Dumb question but why can't they just make the SNAC thing work better so you don't need as much semaglutide? Like, improve the absorption from 1% to 10%?
Not a dumb question — it's actually a major area of pharmaceutical research. The challenge is that peptides are inherently fragile molecules. The GI tract is designed to break down proteins and peptides (that's literally what digestion is). Getting any peptide across the gut lining intact is fighting against biology.
SNAC works by transiently raising local pH in the stomach, which both protects semaglutide from degradation and facilitates transcellular absorption. But even optimized, the physics of moving a 4-kDa peptide across a lipid bilayer membrane is intrinsically inefficient.
Some companies are working on alternative approaches:
But honestly, the more elegant solution is to abandon peptides altogether for oral delivery and use small molecules like orforglipron. That's where the field is heading.
One more thing about OASIS worth discussing: the OASIS-4 trial studied oral semaglutide 50mg in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. The results showed significant improvements in heart failure symptoms, exercise capacity, and weight loss.
This is noteworthy because it expands the potential indications for high-dose oral semaglutide beyond pure weight management. For cardiologists who want to prescribe a GLP-1 for their HFpEF patients but whose patients refuse injections, oral sema 50mg could fill an important niche.
The future isn't just "oral vs. injectable" — it's about matching the right formulation and drug to the right patient population.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standards